JP2016222702A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016222702A5 JP2016222702A5 JP2016147969A JP2016147969A JP2016222702A5 JP 2016222702 A5 JP2016222702 A5 JP 2016222702A5 JP 2016147969 A JP2016147969 A JP 2016147969A JP 2016147969 A JP2016147969 A JP 2016147969A JP 2016222702 A5 JP2016222702 A5 JP 2016222702A5
- Authority
- JP
- Japan
- Prior art keywords
- syndrome
- disease
- autoimmune
- chronic
- allergic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000011580 syndromic disease Diseases 0.000 claims 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 18
- 230000001363 autoimmune Effects 0.000 claims 15
- 201000010099 disease Diseases 0.000 claims 14
- 230000001404 mediated effect Effects 0.000 claims 9
- 230000001154 acute effect Effects 0.000 claims 8
- 206010025135 lupus erythematosus Diseases 0.000 claims 8
- 208000010668 atopic eczema Diseases 0.000 claims 7
- 230000001684 chronic effect Effects 0.000 claims 7
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 7
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 6
- 206010061218 Inflammation Diseases 0.000 claims 6
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 6
- 206010046851 Uveitis Diseases 0.000 claims 6
- 230000004054 inflammatory process Effects 0.000 claims 6
- 201000006417 multiple sclerosis Diseases 0.000 claims 6
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims 5
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 5
- 206010047115 Vasculitis Diseases 0.000 claims 5
- 208000026935 allergic disease Diseases 0.000 claims 5
- 230000000172 allergic effect Effects 0.000 claims 5
- 206010009887 colitis Diseases 0.000 claims 5
- 201000008383 nephritis Diseases 0.000 claims 5
- 208000023275 Autoimmune disease Diseases 0.000 claims 4
- 208000015943 Coeliac disease Diseases 0.000 claims 4
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 4
- 206010020751 Hypersensitivity Diseases 0.000 claims 4
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 4
- 201000009906 Meningitis Diseases 0.000 claims 4
- 208000005225 Opsoclonus-Myoclonus Syndrome Diseases 0.000 claims 4
- 201000004681 Psoriasis Diseases 0.000 claims 4
- 206010063837 Reperfusion injury Diseases 0.000 claims 4
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 4
- 206010042953 Systemic sclerosis Diseases 0.000 claims 4
- 239000000556 agonist Substances 0.000 claims 4
- 208000007502 anemia Diseases 0.000 claims 4
- 206010003246 arthritis Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 206010014599 encephalitis Diseases 0.000 claims 4
- 208000006454 hepatitis Diseases 0.000 claims 4
- 208000027866 inflammatory disease Diseases 0.000 claims 4
- 208000033808 peripheral neuropathy Diseases 0.000 claims 4
- 208000002574 reactive arthritis Diseases 0.000 claims 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 4
- 208000017520 skin disease Diseases 0.000 claims 4
- 206010001889 Alveolitis Diseases 0.000 claims 3
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 claims 3
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- 201000004624 Dermatitis Diseases 0.000 claims 3
- 206010012442 Dermatitis contact Diseases 0.000 claims 3
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 3
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims 3
- 206010021263 IgA nephropathy Diseases 0.000 claims 3
- 208000028622 Immune thrombocytopenia Diseases 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 3
- 208000021642 Muscular disease Diseases 0.000 claims 3
- 201000009623 Myopathy Diseases 0.000 claims 3
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 3
- 208000033464 Reiter syndrome Diseases 0.000 claims 3
- 208000034189 Sclerosis Diseases 0.000 claims 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 3
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 3
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 3
- 201000008937 atopic dermatitis Diseases 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 210000003169 central nervous system Anatomy 0.000 claims 3
- 201000003278 cryoglobulinemia Diseases 0.000 claims 3
- 201000002491 encephalomyelitis Diseases 0.000 claims 3
- 230000002124 endocrine Effects 0.000 claims 3
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims 3
- 208000007475 hemolytic anemia Diseases 0.000 claims 3
- 231100000283 hepatitis Toxicity 0.000 claims 3
- 230000009610 hypersensitivity Effects 0.000 claims 3
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims 3
- 230000002757 inflammatory effect Effects 0.000 claims 3
- 210000000265 leukocyte Anatomy 0.000 claims 3
- 206010028417 myasthenia gravis Diseases 0.000 claims 3
- 230000002107 myocardial effect Effects 0.000 claims 3
- 201000001119 neuropathy Diseases 0.000 claims 3
- 230000007823 neuropathy Effects 0.000 claims 3
- 201000008482 osteoarthritis Diseases 0.000 claims 3
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 208000030507 AIDS Diseases 0.000 claims 2
- 208000026872 Addison Disease Diseases 0.000 claims 2
- 201000004384 Alopecia Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 206010002198 Anaphylactic reaction Diseases 0.000 claims 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 2
- 206010003591 Ataxia Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000004300 Atrophic Gastritis Diseases 0.000 claims 2
- 208000002691 Choroiditis Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 208000006313 Delayed Hypersensitivity Diseases 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 208000017701 Endocrine disease Diseases 0.000 claims 2
- 206010014950 Eosinophilia Diseases 0.000 claims 2
- 206010015150 Erythema Diseases 0.000 claims 2
- 206010015226 Erythema nodosum Diseases 0.000 claims 2
- 201000003542 Factor VIII deficiency Diseases 0.000 claims 2
- 206010016717 Fistula Diseases 0.000 claims 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims 2
- 201000005569 Gout Diseases 0.000 claims 2
- 206010018634 Gouty Arthritis Diseases 0.000 claims 2
- 206010018691 Granuloma Diseases 0.000 claims 2
- 208000015023 Graves' disease Diseases 0.000 claims 2
- 208000001204 Hashimoto Disease Diseases 0.000 claims 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 2
- 208000009292 Hemophilia A Diseases 0.000 claims 2
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims 2
- 241000725303 Human immunodeficiency virus Species 0.000 claims 2
- 208000000038 Hypoparathyroidism Diseases 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 206010025280 Lymphocytosis Diseases 0.000 claims 2
- 206010028372 Muscular weakness Diseases 0.000 claims 2
- 208000000112 Myalgia Diseases 0.000 claims 2
- 206010028665 Myxoedema Diseases 0.000 claims 2
- 206010029240 Neuritis Diseases 0.000 claims 2
- 206010034277 Pemphigoid Diseases 0.000 claims 2
- 206010036105 Polyneuropathy Diseases 0.000 claims 2
- 208000003971 Posterior uveitis Diseases 0.000 claims 2
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 claims 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 2
- 206010072148 Stiff-Person syndrome Diseases 0.000 claims 2
- 206010042742 Sympathetic ophthalmia Diseases 0.000 claims 2
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 claims 2
- 208000024780 Urticaria Diseases 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- 231100000360 alopecia Toxicity 0.000 claims 2
- 230000036783 anaphylactic response Effects 0.000 claims 2
- 208000003455 anaphylaxis Diseases 0.000 claims 2
- 208000002399 aphthous stomatitis Diseases 0.000 claims 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 2
- 208000016644 chronic atrophic gastritis Diseases 0.000 claims 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 2
- 208000024376 chronic urticaria Diseases 0.000 claims 2
- 208000010247 contact dermatitis Diseases 0.000 claims 2
- 201000001981 dermatomyositis Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 208000030172 endocrine system disease Diseases 0.000 claims 2
- 206010014801 endophthalmitis Diseases 0.000 claims 2
- 210000003979 eosinophil Anatomy 0.000 claims 2
- 231100000321 erythema Toxicity 0.000 claims 2
- 208000030533 eye disease Diseases 0.000 claims 2
- 230000003890 fistula Effects 0.000 claims 2
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 claims 2
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 208000003532 hypothyroidism Diseases 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 201000002364 leukopenia Diseases 0.000 claims 2
- 231100001022 leukopenia Toxicity 0.000 claims 2
- 230000036473 myasthenia Effects 0.000 claims 2
- 208000003786 myxedema Diseases 0.000 claims 2
- 230000000414 obstructive effect Effects 0.000 claims 2
- 208000012111 paraneoplastic syndrome Diseases 0.000 claims 2
- 208000005987 polymyositis Diseases 0.000 claims 2
- 230000007824 polyneuropathy Effects 0.000 claims 2
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 claims 2
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
- 230000002207 retinal effect Effects 0.000 claims 2
- 201000003068 rheumatic fever Diseases 0.000 claims 2
- 201000000306 sarcoidosis Diseases 0.000 claims 2
- 201000005671 spondyloarthropathy Diseases 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 208000008732 thymoma Diseases 0.000 claims 2
- 206010043778 thyroiditis Diseases 0.000 claims 2
- 201000008827 tuberculosis Diseases 0.000 claims 2
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 102100033051 40S ribosomal protein S19 Human genes 0.000 claims 1
- 206010056508 Acquired epidermolysis bullosa Diseases 0.000 claims 1
- 206010001076 Acute sinusitis Diseases 0.000 claims 1
- 206010001257 Adenoviral conjunctivitis Diseases 0.000 claims 1
- 206010062269 Adrenalitis Diseases 0.000 claims 1
- 208000008190 Agammaglobulinemia Diseases 0.000 claims 1
- 201000010000 Agranulocytosis Diseases 0.000 claims 1
- 206010027654 Allergic conditions Diseases 0.000 claims 1
- 208000024985 Alport syndrome Diseases 0.000 claims 1
- 206010001881 Alveolar proteinosis Diseases 0.000 claims 1
- 208000035939 Alveolitis allergic Diseases 0.000 claims 1
- 206010001935 American trypanosomiasis Diseases 0.000 claims 1
- 206010002412 Angiocentric lymphomas Diseases 0.000 claims 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 1
- 208000025494 Aortic disease Diseases 0.000 claims 1
- 208000032467 Aplastic anaemia Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 206010003267 Arthritis reactive Diseases 0.000 claims 1
- 206010003487 Aspergilloma Diseases 0.000 claims 1
- 206010003694 Atrophy Diseases 0.000 claims 1
- 206010071576 Autoimmune aplastic anaemia Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 206010064539 Autoimmune myocarditis Diseases 0.000 claims 1
- 206010055128 Autoimmune neutropenia Diseases 0.000 claims 1
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 claims 1
- 208000022106 Autoimmune polyendocrinopathy type 2 Diseases 0.000 claims 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 208000006373 Bell palsy Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 208000033932 Blackfan-Diamond anemia Diseases 0.000 claims 1
- 208000019838 Blood disease Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 206010006448 Bronchiolitis Diseases 0.000 claims 1
- 206010006473 Bronchopulmonary aspergillosis Diseases 0.000 claims 1
- 201000002829 CREST Syndrome Diseases 0.000 claims 1
- 241000244203 Caenorhabditis elegans Species 0.000 claims 1
- 208000025985 Central nervous system inflammatory disease Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 208000024699 Chagas disease Diseases 0.000 claims 1
- 206010008748 Chorea Diseases 0.000 claims 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 1
- 206010008909 Chronic Hepatitis Diseases 0.000 claims 1
- 208000008818 Chronic Mucocutaneous Candidiasis Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009137 Chronic sinusitis Diseases 0.000 claims 1
- 102100026735 Coagulation factor VIII Human genes 0.000 claims 1
- 102000008186 Collagen Human genes 0.000 claims 1
- 108010035532 Collagen Proteins 0.000 claims 1
- 208000027932 Collagen disease Diseases 0.000 claims 1
- 206010053138 Congenital aplastic anaemia Diseases 0.000 claims 1
- 206010010619 Congenital rubella infection Diseases 0.000 claims 1
- 208000014311 Cushing syndrome Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010011878 Deafness Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000016192 Demyelinating disease Diseases 0.000 claims 1
- 208000001490 Dengue Diseases 0.000 claims 1
- 206010012310 Dengue fever Diseases 0.000 claims 1
- 206010012434 Dermatitis allergic Diseases 0.000 claims 1
- 206010048768 Dermatosis Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 201000004449 Diamond-Blackfan anemia Diseases 0.000 claims 1
- 201000003066 Diffuse Scleroderma Diseases 0.000 claims 1
- 208000001708 Dupuytren contracture Diseases 0.000 claims 1
- 208000005235 Echovirus Infections Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 208000004232 Enteritis Diseases 0.000 claims 1
- 206010014952 Eosinophilia myalgia syndrome Diseases 0.000 claims 1
- 206010014954 Eosinophilic fasciitis Diseases 0.000 claims 1
- 206010014989 Epidermolysis bullosa Diseases 0.000 claims 1
- 206010015108 Epstein-Barr virus infection Diseases 0.000 claims 1
- 206010015218 Erythema multiforme Diseases 0.000 claims 1
- 208000027445 Farmer Lung Diseases 0.000 claims 1
- 201000006353 Filariasis Diseases 0.000 claims 1
- 206010016952 Food poisoning Diseases 0.000 claims 1
- 208000019331 Foodborne disease Diseases 0.000 claims 1
- 208000036495 Gastritis atrophic Diseases 0.000 claims 1
- 208000007465 Giant cell arteritis Diseases 0.000 claims 1
- 208000003807 Graves Disease Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 208000008899 Habitual abortion Diseases 0.000 claims 1
- 206010018910 Haemolysis Diseases 0.000 claims 1
- 208000018565 Hemochromatosis Diseases 0.000 claims 1
- 208000032843 Hemorrhage Diseases 0.000 claims 1
- 206010062639 Herpes dermatitis Diseases 0.000 claims 1
- 208000007514 Herpes zoster Diseases 0.000 claims 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 1
- 208000004454 Hyperalgesia Diseases 0.000 claims 1
- 208000035154 Hyperesthesia Diseases 0.000 claims 1
- 206010020850 Hyperthyroidism Diseases 0.000 claims 1
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 claims 1
- 206010058359 Hypogonadism Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 208000016300 Idiopathic chronic eosinophilic pneumonia Diseases 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
- 208000004575 Infectious Arthritis Diseases 0.000 claims 1
- 206010022941 Iridocyclitis Diseases 0.000 claims 1
- 208000012528 Juvenile dermatomyositis Diseases 0.000 claims 1
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 claims 1
- 241000222722 Leishmania <genus> Species 0.000 claims 1
- 208000004554 Leishmaniasis Diseases 0.000 claims 1
- 206010024229 Leprosy Diseases 0.000 claims 1
- 201000001779 Leukocyte adhesion deficiency Diseases 0.000 claims 1
- 208000012309 Linear IgA disease Diseases 0.000 claims 1
- 208000004883 Lipoid Nephrosis Diseases 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 206010025130 Lupus encephalitis Diseases 0.000 claims 1
- 208000016604 Lyme disease Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims 1
- 206010028080 Mucocutaneous candidiasis Diseases 0.000 claims 1
- 208000005647 Mumps Diseases 0.000 claims 1
- 206010028424 Myasthenic syndrome Diseases 0.000 claims 1
- 206010028594 Myocardial fibrosis Diseases 0.000 claims 1
- 208000009525 Myocarditis Diseases 0.000 claims 1
- 201000002481 Myositis Diseases 0.000 claims 1
- 206010028703 Nail psoriasis Diseases 0.000 claims 1
- 206010051606 Necrotising colitis Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010033661 Pancytopenia Diseases 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 208000008071 Parvoviridae Infections Diseases 0.000 claims 1
- 206010057343 Parvovirus infection Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 208000008469 Peptic Ulcer Diseases 0.000 claims 1
- 206010034620 Peripheral sensory neuropathy Diseases 0.000 claims 1
- 208000031845 Pernicious anaemia Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 206010036030 Polyarthritis Diseases 0.000 claims 1
- 206010065159 Polychondritis Diseases 0.000 claims 1
- 206010036242 Post vaccination syndrome Diseases 0.000 claims 1
- 206010036631 Presenile dementia Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 206010036697 Primary hypothyroidism Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 208000004430 Pulmonary Aspergillosis Diseases 0.000 claims 1
- 208000003670 Pure Red-Cell Aplasia Diseases 0.000 claims 1
- 206010037575 Pustular psoriasis Diseases 0.000 claims 1
- 206010037596 Pyelonephritis Diseases 0.000 claims 1
- 206010071141 Rasmussen encephalitis Diseases 0.000 claims 1
- 208000004160 Rasmussen subacute encephalitis Diseases 0.000 claims 1
- 208000003782 Raynaud disease Diseases 0.000 claims 1
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 1
- 208000021329 Refractory celiac disease Diseases 0.000 claims 1
- 208000025747 Rheumatic disease Diseases 0.000 claims 1
- 241000710799 Rubella virus Species 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 201000010001 Silicosis Diseases 0.000 claims 1
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 claims 1
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 claims 1
- 206010061373 Sudden Hearing Loss Diseases 0.000 claims 1
- 208000033809 Suppuration Diseases 0.000 claims 1
- 208000027522 Sydenham chorea Diseases 0.000 claims 1
- 230000005867 T cell response Effects 0.000 claims 1
- 206010043189 Telangiectasia Diseases 0.000 claims 1
- 206010043781 Thyroiditis chronic Diseases 0.000 claims 1
- 206010043784 Thyroiditis subacute Diseases 0.000 claims 1
- 206010044248 Toxic shock syndrome Diseases 0.000 claims 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims 1
- 208000003441 Transfusion reaction Diseases 0.000 claims 1
- 241000223109 Trypanosoma cruzi Species 0.000 claims 1
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims 1
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 241000282485 Vulpes vulpes Species 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 208000037855 acute anterior uveitis Diseases 0.000 claims 1
- 208000026816 acute arthritis Diseases 0.000 claims 1
- 208000002029 allergic contact dermatitis Diseases 0.000 claims 1
- 201000010435 allergic urticaria Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 208000004631 alopecia areata Diseases 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000000469 anti-sperm effect Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 230000002917 arthritic effect Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000001977 ataxic effect Effects 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 201000009780 autoimmune polyendocrine syndrome type 2 Diseases 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 208000010928 autoimmune thyroid disease Diseases 0.000 claims 1
- 201000004982 autoimmune uveitis Diseases 0.000 claims 1
- 230000005784 autoimmunity Effects 0.000 claims 1
- 208000005980 beta thalassemia Diseases 0.000 claims 1
- 208000015440 bird fancier lung Diseases 0.000 claims 1
- 208000034158 bleeding Diseases 0.000 claims 1
- 230000000740 bleeding effect Effects 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 230000036772 blood pressure Effects 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 210000000133 brain stem Anatomy 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 208000000594 bullous pemphigoid Diseases 0.000 claims 1
- 230000007969 cellular immunity Effects 0.000 claims 1
- 208000025434 cerebellar degeneration Diseases 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 201000010415 childhood type dermatomyositis Diseases 0.000 claims 1
- 201000004709 chorioretinitis Diseases 0.000 claims 1
- 201000009323 chronic eosinophilic pneumonia Diseases 0.000 claims 1
- 208000030949 chronic idiopathic urticaria Diseases 0.000 claims 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims 1
- 206010072757 chronic spontaneous urticaria Diseases 0.000 claims 1
- 230000001886 ciliary effect Effects 0.000 claims 1
- 229920001436 collagen Polymers 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 208000025729 dengue disease Diseases 0.000 claims 1
- 201000010064 diabetes insipidus Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 230000003292 diminished effect Effects 0.000 claims 1
- 208000032625 disorder of ear Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 206010014665 endocarditis Diseases 0.000 claims 1
- 208000021373 epidemic keratoconjunctivitis Diseases 0.000 claims 1
- 210000002615 epidermis Anatomy 0.000 claims 1
- 201000011114 epidermolysis bullosa acquisita Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000002449 erythroblastic effect Effects 0.000 claims 1
- 208000022195 farmer lung disease Diseases 0.000 claims 1
- 230000002349 favourable effect Effects 0.000 claims 1
- 208000001031 fetal erythroblastosis Diseases 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 1
- 230000002710 gonadal effect Effects 0.000 claims 1
- 210000003714 granulocyte Anatomy 0.000 claims 1
- 230000010370 hearing loss Effects 0.000 claims 1
- 231100000888 hearing loss Toxicity 0.000 claims 1
- 208000016354 hearing loss disease Diseases 0.000 claims 1
- 208000014951 hematologic disease Diseases 0.000 claims 1
- 208000018706 hematopoietic system disease Diseases 0.000 claims 1
- 201000001505 hemoglobinuria Diseases 0.000 claims 1
- 230000008588 hemolysis Effects 0.000 claims 1
- 208000003215 hereditary nephritis Diseases 0.000 claims 1
- 102000057058 human VSIR Human genes 0.000 claims 1
- 206010020718 hyperplasia Diseases 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 claims 1
- 230000002989 hypothyroidism Effects 0.000 claims 1
- 208000009326 ileitis Diseases 0.000 claims 1
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 201000006747 infectious mononucleosis Diseases 0.000 claims 1
- 208000000509 infertility Diseases 0.000 claims 1
- 230000036512 infertility Effects 0.000 claims 1
- 231100000535 infertility Toxicity 0.000 claims 1
- 230000008595 infiltration Effects 0.000 claims 1
- 238000001764 infiltration Methods 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 201000004614 iritis Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 208000018937 joint inflammation Diseases 0.000 claims 1
- 206010023332 keratitis Diseases 0.000 claims 1
- 201000010666 keratoconjunctivitis Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 claims 1
- 230000002197 limbic effect Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 230000000527 lymphocytic effect Effects 0.000 claims 1
- 208000005158 lymphoid interstitial pneumonia Diseases 0.000 claims 1
- 208000006116 lymphomatoid granulomatosis Diseases 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000002050 maxilla Anatomy 0.000 claims 1
- 210000004379 membrane Anatomy 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 claims 1
- 208000008275 microscopic colitis Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 206010065579 multifocal motor neuropathy Diseases 0.000 claims 1
- 208000037890 multiple organ injury Diseases 0.000 claims 1
- 208000010805 mumps infectious disease Diseases 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- 208000004995 necrotizing enterocolitis Diseases 0.000 claims 1
- 208000009928 nephrosis Diseases 0.000 claims 1
- 231100001027 nephrosis Toxicity 0.000 claims 1
- 230000002232 neuromuscular Effects 0.000 claims 1
- 208000028780 ocular motility disease Diseases 0.000 claims 1
- 201000005737 orchitis Diseases 0.000 claims 1
- 208000030346 palmar fibromatosis Diseases 0.000 claims 1
- 208000011906 peptic ulcer disease Diseases 0.000 claims 1
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 claims 1
- 208000006473 polyradiculopathy Diseases 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 201000009732 pulmonary eosinophilia Diseases 0.000 claims 1
- 208000009954 pyoderma gangrenosum Diseases 0.000 claims 1
- 206010061928 radiculitis Diseases 0.000 claims 1
- 208000034213 recurrent susceptibility to 1 pregnancy loss Diseases 0.000 claims 1
- 210000003289 regulatory T cell Anatomy 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 201000004409 schistosomiasis Diseases 0.000 claims 1
- 210000003786 sclera Anatomy 0.000 claims 1
- 210000000697 sensory organ Anatomy 0.000 claims 1
- 201000005572 sensory peripheral neuropathy Diseases 0.000 claims 1
- 201000001223 septic arthritis Diseases 0.000 claims 1
- 201000006476 shipyard eye Diseases 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 201000006923 sphenoid sinusitis Diseases 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 230000003393 splenic effect Effects 0.000 claims 1
- 201000007497 subacute thyroiditis Diseases 0.000 claims 1
- 208000009056 telangiectasis Diseases 0.000 claims 1
- 206010043207 temporal arteritis Diseases 0.000 claims 1
- 206010043554 thrombocytopenia Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 230000000451 tissue damage Effects 0.000 claims 1
- 231100000827 tissue damage Toxicity 0.000 claims 1
- 230000001256 tonic effect Effects 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
- 208000009174 transverse myelitis Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 210000001745 uvea Anatomy 0.000 claims 1
- 230000006492 vascular dysfunction Effects 0.000 claims 1
- 230000024883 vasodilation Effects 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/732,371 US8231872B2 (en) | 2005-04-25 | 2010-03-26 | Regulatory T cell mediator proteins and uses thereof |
| US12/732,371 | 2010-03-26 | ||
| US39043410P | 2010-10-06 | 2010-10-06 | |
| US61/390,434 | 2010-10-06 | ||
| US201161436379P | 2011-01-26 | 2011-01-26 | |
| US61/436,379 | 2011-01-26 | ||
| US201161449882P | 2011-03-07 | 2011-03-07 | |
| US61/449,882 | 2011-03-07 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013502683A Division JP6034283B2 (ja) | 2010-03-26 | 2011-03-25 | Ｖｉｓｔａ制御性ｔ細胞メディエータタンパク質、ｖｉｓｔａ結合剤、およびその使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017132677A Division JP6712716B2 (ja) | 2010-03-26 | 2017-07-06 | Ｖｉｓｔａ制御性ｔ細胞メディエータタンパク質、ｖｉｓｔａ結合剤、およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016222702A JP2016222702A (ja) | 2016-12-28 |
| JP2016222702A5 true JP2016222702A5 (enExample) | 2017-06-22 |
| JP6175170B2 JP6175170B2 (ja) | 2017-08-02 |
Family
ID=44673904
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013502683A Expired - Fee Related JP6034283B2 (ja) | 2010-03-26 | 2011-03-25 | Ｖｉｓｔａ制御性ｔ細胞メディエータタンパク質、ｖｉｓｔａ結合剤、およびその使用 |
| JP2016147969A Active JP6175170B2 (ja) | 2010-03-26 | 2016-07-28 | Ｖｉｓｔａ制御性ｔ細胞メディエータタンパク質、ｖｉｓｔａ結合剤、およびその使用 |
| JP2017132677A Active JP6712716B2 (ja) | 2010-03-26 | 2017-07-06 | Ｖｉｓｔａ制御性ｔ細胞メディエータタンパク質、ｖｉｓｔａ結合剤、およびその使用 |
| JP2020073996A Pending JP2020128381A (ja) | 2010-03-26 | 2020-04-17 | Ｖｉｓｔａ制御性ｔ細胞メディエータタンパク質、ｖｉｓｔａ結合剤、およびその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013502683A Expired - Fee Related JP6034283B2 (ja) | 2010-03-26 | 2011-03-25 | Ｖｉｓｔａ制御性ｔ細胞メディエータタンパク質、ｖｉｓｔａ結合剤、およびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017132677A Active JP6712716B2 (ja) | 2010-03-26 | 2017-07-06 | Ｖｉｓｔａ制御性ｔ細胞メディエータタンパク質、ｖｉｓｔａ結合剤、およびその使用 |
| JP2020073996A Pending JP2020128381A (ja) | 2010-03-26 | 2020-04-17 | Ｖｉｓｔａ制御性ｔ細胞メディエータタンパク質、ｖｉｓｔａ結合剤、およびその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US9631018B2 (enExample) |
| EP (2) | EP2552947A4 (enExample) |
| JP (4) | JP6034283B2 (enExample) |
| KR (1) | KR101882523B1 (enExample) |
| CN (2) | CN107098958B (enExample) |
| AU (5) | AU2011230537C1 (enExample) |
| BR (1) | BR112012024565B1 (enExample) |
| CA (2) | CA3079122A1 (enExample) |
| IL (2) | IL222118B (enExample) |
| MX (2) | MX374075B (enExample) |
| NZ (2) | NZ602634A (enExample) |
| WO (1) | WO2011120013A2 (enExample) |
Families Citing this family (101)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8231872B2 (en) | 2005-04-25 | 2012-07-31 | The Trustees Of Dartmouth College | Regulatory T cell mediator proteins and uses thereof |
| WO2006116181A2 (en) * | 2005-04-25 | 2006-11-02 | Trustees Of Dartmouth College | Regulatory t cell mediator proteins and uses thereof |
| BR112012024565B1 (pt) | 2010-03-26 | 2022-02-08 | Trustees Of Dartmouth College | Proteína de fusão vista imunossupressora multimérica isolada ou recombinante e composição |
| US10745467B2 (en) | 2010-03-26 | 2020-08-18 | The Trustees Of Dartmouth College | VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders |
| US20150231215A1 (en) | 2012-06-22 | 2015-08-20 | Randolph J. Noelle | VISTA Antagonist and Methods of Use |
| AU2012260601B2 (en) | 2011-05-25 | 2018-02-01 | Innate Pharma, S.A. | Anti-KIR antibodies for the treatment of inflammatory disorders |
| US20140335117A1 (en) | 2011-10-07 | 2014-11-13 | Skau Aps | Identification and Attenuation of the Immunosuppressive Domains in Fusion Proteins of Enveloped RNA Viruses |
| US9890215B2 (en) | 2012-06-22 | 2018-02-13 | King's College London | Vista modulators for diagnosis and treatment of cancer |
| FI3421486T3 (fi) * | 2012-06-22 | 2023-12-15 | Dartmouth College | Uusia vista-ig-rakenteita ja vista-ig:n käyttö autoimmuuni-, allergia- ja tulehdushäiriöiden hoitamiseksi |
| JP6368308B2 (ja) * | 2012-09-07 | 2018-08-01 | トラスティーズ・オブ・ダートマス・カレッジ | 癌の診断および治療のためのｖｉｓｔａ調節剤 |
| US11484567B2 (en) * | 2013-04-10 | 2022-11-01 | Aarhus Universitet | Use of immune suppressive domains as medicaments |
| EP3003390B1 (en) * | 2013-06-06 | 2021-07-07 | Pierre Fabre Médicament | Anti-c10orf54 antibodies and uses thereof |
| KR102393711B1 (ko) * | 2013-10-17 | 2022-05-04 | 더 제너럴 하스피탈 코포레이션 | 자가면역 질환의 치료에 반응하는 대상체의 식별 방법 및 그의 치료를 위한 조성물 |
| US11014987B2 (en) | 2013-12-24 | 2021-05-25 | Janssen Pharmaceutics Nv | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same |
| US10273301B2 (en) | 2013-12-24 | 2019-04-30 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments |
| CA2936926C (en) * | 2014-01-14 | 2023-08-29 | Mark Spaller | Vista antagonist and methods of use |
| WO2015191881A2 (en) | 2014-06-11 | 2015-12-17 | Green Kathy A | Use of vista agonists and antagonists to suppress or enhance humoral immunity |
| CN120555373A (zh) | 2014-07-16 | 2025-08-29 | 特兰斯吉恩股份有限公司 | 用于表达免疫检查点调节因子的溶瘤病毒 |
| JP6885728B2 (ja) * | 2014-11-06 | 2021-06-16 | キングス・カレッジ・ロンドン | Ｖｉｓｔａアンタゴニスト及び使用の方法 |
| WO2016090347A1 (en) * | 2014-12-05 | 2016-06-09 | Immunext, Inc. | Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators |
| SI3333191T1 (sl) * | 2014-12-11 | 2021-03-31 | Pierre Fabre Medicament | Proti C10ORF54 protitelesa in uporaba le-teh |
| CN112481211B (zh) * | 2015-01-26 | 2024-07-05 | 儿童医院公司 | 免疫调节性提高的细胞及其使用和生产方法 |
| US20160220636A1 (en) * | 2015-01-29 | 2016-08-04 | Sarah Bacus | Method of treating auto-immune or inflammatory diseases using b7 family proteins of derivatives thereof |
| EP3722314A1 (en) * | 2015-06-24 | 2020-10-14 | Janssen Pharmaceutica NV | Anti-vista antibodies and fragments |
| HK1254976A1 (zh) | 2015-07-31 | 2019-08-02 | University Of Florida Research Foundation, Inc. | 造血干细胞和抗癌免疫检查点抑制剂的组合疗法 |
| EP3347026A4 (en) * | 2015-09-09 | 2019-05-08 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | GENEMANIPULATION OF MACROPHAGES FOR IMMUNOTHERAPY |
| CN109069626A (zh) | 2016-02-12 | 2018-12-21 | 詹森药业有限公司 | 抗-vista(b7h5)抗体 |
| WO2017175058A1 (en) | 2016-04-07 | 2017-10-12 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same |
| US11525000B2 (en) * | 2016-04-15 | 2022-12-13 | Immunext, Inc. | Anti-human VISTA antibodies and use thereof |
| WO2017181109A1 (en) * | 2016-04-15 | 2017-10-19 | Michael Molloy | Anti-human vista antibodies and use thereof |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TW201825674A (zh) | 2016-09-09 | 2018-07-16 | 美商艾斯合顧問有限公司 | 表現雙特異性接合分子的溶瘤病毒 |
| EP3568159A4 (en) * | 2017-01-11 | 2020-08-05 | Bristol-Myers Squibb Company | PSGL-1 ANTAGONISTS AND THEIR USES |
| EP3585410B9 (en) | 2017-02-27 | 2023-10-04 | Shattuck Labs, Inc. | Vsig8-based chimeric proteins |
| CA3054067A1 (en) * | 2017-03-14 | 2018-09-20 | Five Prime Therapeutics, Inc. | Antibodies binding to vista at acidic ph |
| WO2018195772A1 (en) * | 2017-04-25 | 2018-11-01 | Sun Yat-Sen University | Pd-1h as target in treatement of asthma |
| CN107149680A (zh) * | 2017-04-27 | 2017-09-12 | 中山大学 | Pd‑1h激动剂在哮喘治疗中的应用 |
| WO2018201282A1 (en) * | 2017-05-02 | 2018-11-08 | Sun Yat-Sen University | Pd-1h as target in modulation of pool size of inducible regulatory t cells |
| CN107137712A (zh) * | 2017-05-09 | 2017-09-08 | 中山大学 | Pd‑1h激动剂或拮抗剂的应用 |
| WO2018218137A1 (en) | 2017-05-25 | 2018-11-29 | Leidos, Inc. | Pd-1 and ctla-4 dual inhibitor peptides |
| WO2019133454A2 (en) | 2017-12-29 | 2019-07-04 | Shaw Gray D | Methods to improve the therapeutic index of activated t cells |
| AU2018410849B2 (en) | 2018-02-27 | 2025-02-27 | Leidos, Inc. | PD-1 peptide inhibitors |
| PE20210290A1 (es) | 2018-03-21 | 2021-02-11 | Five Prime Therapeutics Inc | ANTICUERPOS DE UNION A VISTA A pH ACIDO |
| CN110305221B (zh) * | 2018-03-27 | 2022-10-11 | 孙嘉琳 | 一种增强型抗肿瘤融合蛋白及制备方法及用途 |
| CN110305220B (zh) * | 2018-03-27 | 2022-10-11 | 孙嘉琳 | 一种癌靶向增强型抗肿瘤融合蛋白及制备方法及用途 |
| US20190300610A1 (en) | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Pte. Ltd. | Vista antigen-binding molecules |
| GB201814562D0 (en) | 2018-09-07 | 2018-10-24 | Hummingbird Bioscience Pte Ltd | Vista antigen-binding molecules |
| WO2019185163A1 (en) | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Holdings Pte. Ltd. | Vista antigen-binding molecules |
| CN108743590A (zh) * | 2018-05-17 | 2018-11-06 | 中国药科大学 | 与vista具有亲和力的小分子化合物及其用途 |
| WO2019226922A1 (en) * | 2018-05-24 | 2019-11-28 | Rush University Medical Center | Icosl for use as a renal therapeutic |
| BR112021000303A2 (pt) | 2018-07-11 | 2021-04-13 | Five Prime Therapeutics, Inc. | Anticorpos que se ligam a vista em ph ácido |
| AU2019309472A1 (en) * | 2018-07-24 | 2021-03-18 | Good T Cells, Inc. | Composition for preventing or treating immune-related diseases |
| WO2020183011A1 (en) | 2019-03-14 | 2020-09-17 | Institut Curie | Htr1d inhibitors and uses thereof in the treatment of cancer |
| CN119143860A (zh) | 2019-03-29 | 2024-12-17 | 居里研究所 | 具有经修饰的生物活性的白介素-2变体 |
| JP7606471B2 (ja) | 2019-05-22 | 2024-12-25 | レイドス， インコーポレイテッド | Ｌａｇ３結合ペプチド |
| CN110642950B (zh) * | 2019-07-25 | 2021-10-01 | 广东新征程生命科学有限公司 | 一种人源化t细胞活化的v域免疫抑制因子抗原结合片段 |
| WO2021078910A1 (en) | 2019-10-22 | 2021-04-29 | Institut Curie | Immunotherapy targeting tumor neoantigenic peptides |
| EP3824954A1 (en) | 2019-11-22 | 2021-05-26 | Centre National de la Recherche Scientifique | Device, apparatus and method for minibeam radiation therapy |
| JP2023508996A (ja) * | 2019-12-31 | 2023-03-06 | キネート バイオファーマ インク． | Ｃｄｋ１２／１３阻害剤を用いる癌の処置 |
| WO2021224186A1 (en) | 2020-05-04 | 2021-11-11 | Institut Curie | New pyridine derivatives as radiosensitizers |
| AU2021275489A1 (en) | 2020-05-20 | 2022-12-01 | Centre National De La Recherche Scientifique - Cnrs - | Single domain antibodies and their use in cancer therapies |
| CN111549072B (zh) * | 2020-06-03 | 2022-09-13 | 上海南方模式生物科技股份有限公司 | Vista基因人源化动物细胞及动物模型的构建方法与应用 |
| EP4161952A1 (en) | 2020-06-04 | 2023-04-12 | Leidos, Inc. | Immunomodulatory compounds |
| US11578102B2 (en) | 2020-07-31 | 2023-02-14 | Leidos, Inc. | LAG3 binding peptides |
| US11987646B2 (en) | 2020-10-12 | 2024-05-21 | Leidos, Inc. | Immunomodulatory peptides |
| WO2022079270A1 (en) | 2020-10-16 | 2022-04-21 | Université D'aix-Marseille | Anti-gpc4 single domain antibodies |
| US20230303604A1 (en) | 2020-10-20 | 2023-09-28 | Institut Curie | Metallic trans-(n-heterocyclic carbene)-amine-platinum complexes and uses thereof for treating cancer |
| EP4247352A1 (en) | 2020-11-18 | 2023-09-27 | Institut Curie | Dimers of biguanidines and their therapeutic uses |
| CN112530581B (zh) * | 2020-12-03 | 2023-11-21 | 安徽医科大学第一附属医院 | 一种前列腺癌患者的免疫分子分类系统及其应用 |
| CN117916271A (zh) | 2021-01-14 | 2024-04-19 | 居里研究所 | Her2单域抗体变体及其car |
| WO2022189618A1 (en) | 2021-03-12 | 2022-09-15 | Institut Curie | Nitrogen-containing heterocycles as radiosensitizers |
| CN112940125B (zh) * | 2021-04-25 | 2022-04-12 | 福州迈新生物技术开发有限公司 | 抗vista蛋白的单克隆抗体及其细胞株、制备方法和应用 |
| EP4337763A1 (en) | 2021-05-10 | 2024-03-20 | Institut Curie | Methods for the treatment of cancer, inflammatory diseases and autoimmune diseases |
| GB202108446D0 (en) | 2021-06-14 | 2021-07-28 | Hummingbird Bioscience Holdings Pte Ltd | Cells expressing VISTA antigen-binding molecules |
| US20250135232A1 (en) | 2021-08-05 | 2025-05-01 | Institut Curie | Scanning dynamic device for minibeams production |
| US20250313631A1 (en) | 2021-09-16 | 2025-10-09 | Hummingbird Bioscience Pte. Ltd. | Treatment and prevention of cancer using vista antigen-binding molecules |
| WO2023041744A1 (en) | 2021-09-17 | 2023-03-23 | Institut Curie | Bet inhibitors for treating pab1 deficient cancer |
| WO2023046979A1 (en) | 2021-09-27 | 2023-03-30 | Hummingbird Bioscience Pte. Ltd. | Treatment and prevention of cancer using vista antigen-binding molecules |
| WO2023089032A1 (en) | 2021-11-19 | 2023-05-25 | Institut Curie | Methods for the treatment of hrd cancer and brca-associated cancer |
| WO2023099763A1 (en) | 2021-12-03 | 2023-06-08 | Institut Curie | Sirt6 inhibitors for use in treating resistant hrd cancer |
| CN119816320A (zh) | 2022-03-24 | 2025-04-11 | 居里研究所 | 靶向胶质母细胞瘤中肿瘤转座元件衍生的新抗原肽的免疫疗法 |
| WO2023187024A1 (en) | 2022-03-31 | 2023-10-05 | Institut Curie | Modified rela protein for inducing interferon expression and engineered immune cells with improved interferon expression |
| JP2025514646A (ja) | 2022-04-07 | 2025-05-09 | アンスティテュ キュリィ | Ｃｄ４０を有するキメラ抗原受容体で改変された骨髄系細胞及び抗がん治療のためのその使用 |
| EP4504245A1 (en) | 2022-04-07 | 2025-02-12 | Institut Curie | Myeloid cells modified by chimeric antigen receptor and uses thereof for anti-cancer therapy |
| KR102769540B1 (ko) * | 2022-08-19 | 2025-02-20 | 울산대학교 산학협력단 | 특발성 폐섬유증 환자의 진단 및 예후예측용 신규 바이오마커 VISTA (V-domain immunoglobulin suppressor of T-cell activation) |
| WO2024062073A1 (en) | 2022-09-22 | 2024-03-28 | Hummingbird Bioscience Pte. Ltd. | Treatment and prevention of cancer using vista antigen-binding molecules |
| JP2025532209A (ja) | 2022-09-26 | 2025-09-29 | アンスティテュ・クリー | Ｉｌ－２を発現する骨髄系細胞及び迅速な抗癌療法のためのその使用 |
| WO2024194401A1 (en) | 2023-03-21 | 2024-09-26 | Institut Curie | Vps4b inhibitor for use in methods for the treatment of hrd cancer |
| WO2024194673A1 (en) | 2023-03-21 | 2024-09-26 | Institut Curie | Methods for the treatment of dedifferentiated liposarcoma |
| WO2024194402A1 (en) | 2023-03-21 | 2024-09-26 | Institut Curie | Farnesyl transferase inhibitor for use in methods for the treatment of hrd cancer |
| WO2024213782A1 (en) | 2023-04-13 | 2024-10-17 | Institut Curie | Methods for the treatment of t-cell acute lymphoblastic leukemia |
| CN116606352B (zh) * | 2023-07-14 | 2023-09-29 | 诺赛联合(北京)生物医学科技有限公司 | 一种抗菌修复功能的组合物凝胶在妇科疾病中的应用 |
| WO2025068393A1 (en) | 2023-09-27 | 2025-04-03 | Institut Curie | Methods for the treatment of fibrotic related diseases |
| WO2025125495A1 (en) | 2023-12-13 | 2025-06-19 | Hummingbird Bioscience Pte. Ltd. | Treatment and prevention of cancer using vista antigen-binding molecules |
| EP4574165A1 (en) | 2023-12-21 | 2025-06-25 | Egle Therapeutics | Immunocytokine for cancer treatment |
| WO2025133175A1 (en) | 2023-12-21 | 2025-06-26 | Egle Therapeutics | Immunocytokine for cancer treatment |
| WO2025158077A1 (en) | 2024-01-26 | 2025-07-31 | Institut Curie | Lipid degraders to trigger ferroptosis in cancer |
| WO2025202450A1 (en) | 2024-03-28 | 2025-10-02 | Institut Curie | Myeloid cells modified by cytokine chimeric receptor and uses thereof |
| EP4624494A1 (en) | 2024-03-29 | 2025-10-01 | Institut Curie | Her2 single domain antibody and uses thereof |
| WO2025210252A1 (en) | 2024-04-05 | 2025-10-09 | Institut Curie | Modulators of fam118b protein for use in therapy |
Family Cites Families (232)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US71436A (en) * | 1867-11-26 | Xnoeis a adkins | ||
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| NO812612L (no) | 1980-08-06 | 1982-02-08 | Ferring Pharma Ltd | Enzym-inhibitorer. |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US4517288A (en) | 1981-01-23 | 1985-05-14 | American Hospital Supply Corp. | Solid phase system for ligand assay |
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4870009A (en) | 1982-11-22 | 1989-09-26 | The Salk Institute For Biological Studies | Method of obtaining gene product through the generation of transgenic animals |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
| US5288641A (en) | 1984-06-04 | 1994-02-22 | Arch Development Corporation | Herpes Simplex virus as a vector |
| US4736866B1 (en) | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals | |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4699880A (en) | 1984-09-25 | 1987-10-13 | Immunomedics, Inc. | Method of producing monoclonal anti-idiotype antibody |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| AU606320B2 (en) | 1985-11-01 | 1991-02-07 | International Genetic Engineering, Inc. | Modular assembly of antibody genes, antibodies prepared thereby and use |
| CA1291031C (en) | 1985-12-23 | 1991-10-22 | Nikolaas C.J. De Jaeger | Method for the detection of specific binding agents and their correspondingbindable substances |
| JPS63502716A (ja) | 1986-03-07 | 1988-10-13 | マサチューセッツ・インステチュート・オブ・テクノロジー | 糖タンパク安定性の強化方法 |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| EP0264166B1 (en) | 1986-04-09 | 1996-08-21 | Genzyme Corporation | Transgenic animals secreting desired proteins into milk |
| US4954617A (en) | 1986-07-07 | 1990-09-04 | Trustees Of Dartmouth College | Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| ATE120761T1 (de) | 1987-05-21 | 1995-04-15 | Creative Biomolecules Inc | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
| US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| CA2006596C (en) | 1988-12-22 | 2000-09-05 | Rika Ishikawa | Chemically-modified g-csf |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US5763266A (en) | 1989-06-15 | 1998-06-09 | The Regents Of The University Of Michigan | Methods, compositions and devices for maintaining and growing human stem and/or hematopoietics cells |
| DE3923279A1 (de) | 1989-07-14 | 1990-01-18 | Will W Prof Dr Minuth | Minusheets ist ein neues produkt, um zellen in beliebigen behaeltnissen in hochdifferenzierter form auf einer moeglichst natuerlichen unterlage zu kultivieren |
| EP0945515A3 (en) | 1989-11-06 | 2002-08-21 | Cell Genesys, Inc. | Production of proteins using homologous recombination |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5272071A (en) | 1989-12-22 | 1993-12-21 | Applied Research Systems Ars Holding N.V. | Method for the modification of the expression characteristics of an endogenous gene of a given cell line |
| US6153737A (en) | 1990-01-11 | 2000-11-28 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| ATE356869T1 (de) | 1990-01-12 | 2007-04-15 | Amgen Fremont Inc | Bildung von xenogenen antikörpern |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| US5521288A (en) | 1990-03-26 | 1996-05-28 | Bristol-Myers Squibb Company | CD28IG fusion protein |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| CA2089661C (en) | 1990-08-29 | 2007-04-03 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| US5747469A (en) | 1991-03-06 | 1998-05-05 | Board Of Regents, The University Of Texas System | Methods and compositions comprising DNA damaging agents and p53 |
| EP0503648B1 (en) | 1991-03-12 | 2000-06-07 | Biogen, Inc. | CD2-Binding domain of lymphocyte function associated antigen 3 |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US5844095A (en) | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
| IL99120A0 (en) | 1991-08-07 | 1992-07-15 | Yeda Res & Dev | Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them |
| US6335434B1 (en) | 1998-06-16 | 2002-01-01 | Isis Pharmaceuticals, Inc., | Nucleosidic and non-nucleosidic folate conjugates |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
| ES2227512T3 (es) | 1991-12-02 | 2005-04-01 | Medical Research Council | Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago. |
| US5776427A (en) | 1992-03-05 | 1998-07-07 | Board Of Regents, The University Of Texas System | Methods for targeting the vasculature of solid tumors |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| AU4116793A (en) | 1992-04-24 | 1993-11-29 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| US6172208B1 (en) | 1992-07-06 | 2001-01-09 | Genzyme Corporation | Oligonucleotides modified with conjugate groups |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| DE69333366T2 (de) | 1992-10-30 | 2004-09-16 | The General Hospital Corp., Boston | Ein neues zellzyklus kontrollprotein |
| GB9223377D0 (en) | 1992-11-04 | 1992-12-23 | Medarex Inc | Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes |
| GB9225453D0 (en) | 1992-12-04 | 1993-01-27 | Medical Res Council | Binding proteins |
| GB9302660D0 (en) | 1993-02-10 | 1993-03-24 | Sihra Kirpal S | A building system |
| AU6445894A (en) | 1993-03-19 | 1994-10-11 | Duke University | Method of treatment of tumors with an antibody binding to tenascin |
| AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| JPH08511166A (ja) | 1993-06-04 | 1996-11-26 | アメリカ合衆国 | Ｔ細胞の増殖を選択的に刺激する方法 |
| EP0714409A1 (en) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
| DE69433036T2 (de) | 1993-09-03 | 2004-05-27 | Isis Pharmaceuticals, Inc., Carlsbad | Aminoderivatisierte nukleoside und oligonukleoside |
| IL114909A (en) | 1994-08-12 | 1999-10-28 | Immunomedics Inc | Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5801155A (en) | 1995-04-03 | 1998-09-01 | Epoch Pharmaceuticals, Inc. | Covalently linked oligonucleotide minor grove binder conjugates |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6410690B1 (en) | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
| US6096532A (en) | 1995-06-07 | 2000-08-01 | Aastrom Biosciences, Inc. | Processor apparatus for use in a system for maintaining and growing biological cells |
| US5985653A (en) | 1995-06-07 | 1999-11-16 | Aastrom Biosciences, Inc. | Incubator apparatus for use in a system for maintaining and growing biological cells |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| GB9517780D0 (en) | 1995-08-31 | 1995-11-01 | Roslin Inst Edinburgh | Biological manipulation |
| GB9517779D0 (en) | 1995-08-31 | 1995-11-01 | Roslin Inst Edinburgh | Biological manipulation |
| US5723125A (en) | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
| US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
| US6444806B1 (en) | 1996-04-30 | 2002-09-03 | Hisamitsu Pharmaceutical Co., Inc. | Conjugates and methods of forming conjugates of oligonucleotides and carbohydrates |
| US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
| US6653104B2 (en) | 1996-10-17 | 2003-11-25 | Immunomedics, Inc. | Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells |
| US6593372B2 (en) | 1996-11-13 | 2003-07-15 | Cold Spring Harbor Laboratory | Therapeutic uses for nitric oxide inhibitors |
| WO1998020865A2 (en) | 1996-11-13 | 1998-05-22 | Cold Spring Harbor Laboratory | Therapeutic uses for nitric oxide inhibitors |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US20060084082A1 (en) * | 1997-03-07 | 2006-04-20 | Human Genome Sciences, Inc. | 186 human secreted proteins |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| WO1999026657A1 (en) | 1997-11-25 | 1999-06-03 | Musc Foundation For Research Development | Inhibitors of nitric oxide synthase |
| US6982323B1 (en) | 1997-12-23 | 2006-01-03 | Alexion Pharmaceuticals, Inc. | Chimeric proteins for diagnosis and treatment of diabetes |
| US6006758A (en) | 1998-02-03 | 1999-12-28 | University Of Maryland | Method and device for the detection and removal of head lice |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| PT2180007E (pt) | 1998-04-20 | 2013-11-25 | Roche Glycart Ag | Engenharia de glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
| US6300319B1 (en) | 1998-06-16 | 2001-10-09 | Isis Pharmaceuticals, Inc. | Targeted oligonucleotide conjugates |
| AU764180B2 (en) | 1998-07-28 | 2003-08-14 | Regents Of The University Of California, The | Nucleic acids encoding a G-protein coupled receptor involved in sensory transduction |
| US6951921B2 (en) | 1998-09-01 | 2005-10-04 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US6924355B2 (en) | 1998-09-01 | 2005-08-02 | Genentech, Inc. | PRO1343 polypeptides |
| US6335437B1 (en) | 1998-09-07 | 2002-01-01 | Isis Pharmaceuticals, Inc. | Methods for the preparation of conjugated oligomers |
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| DE69941156D1 (de) | 1998-11-24 | 2009-09-03 | Bristol Myers Squibb Co | Intranukleärer, gerichteter transport von verbindungen durch das 70kd-hitzeschockprotein |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| KR101155191B1 (ko) | 1999-01-15 | 2012-06-13 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| ES2568899T3 (es) | 1999-04-09 | 2016-05-05 | Kyowa Hakko Kirin Co., Ltd. | Procedimiento para controlar la actividad de una molécula inmunofuncional |
| US6696686B1 (en) | 1999-06-06 | 2004-02-24 | Elgems Ltd. | SPECT for breast cancer detection |
| CA2377513A1 (en) | 1999-06-25 | 2001-01-04 | Universitat Zurich | Hetero-associating coiled-coil peptides |
| AU6058500A (en) | 1999-06-30 | 2001-01-31 | Center For Blood Research, The | Fusion protein and uses thereof |
| JP4944324B2 (ja) | 1999-07-13 | 2012-05-30 | ボルダー バイオテクノロジー， インコーポレイテッド | 免疫グロブリン融合タンパク質 |
| EP2360254A1 (en) * | 1999-08-23 | 2011-08-24 | Dana-Farber Cancer Institute, Inc. | Assays for screening anti-pd-1 antibodies and uses thereof |
| WO2001014424A2 (en) | 1999-08-24 | 2001-03-01 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| US6395437B1 (en) | 1999-10-29 | 2002-05-28 | Advanced Micro Devices, Inc. | Junction profiling using a scanning voltage micrograph |
| ZA200206459B (en) | 2000-03-24 | 2003-08-13 | Pharmacia Corp | Amidino compound and salts thereof useful as nitric oxide synthase inhibitors. |
| SI2857516T1 (sl) | 2000-04-11 | 2017-09-29 | Genentech, Inc. | Multivalentna protitelesa in njihove uporabe |
| US6545170B2 (en) | 2000-04-13 | 2003-04-08 | Pharmacia Corporation | 2-amino-5, 6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors |
| US7417130B2 (en) | 2000-09-08 | 2008-08-26 | University Of Zurich | Collection of repeat proteins comprising repeat modules |
| US6559279B1 (en) | 2000-09-08 | 2003-05-06 | Isis Pharmaceuticals, Inc. | Process for preparing peptide derivatized oligomeric compounds |
| EP1373501A2 (en) | 2000-10-06 | 2004-01-02 | Novartis AG | Targeting molecules for adenoviral vectors |
| JP2004535755A (ja) * | 2000-10-06 | 2004-12-02 | ノバルティス アクチエンゲゼルシャフト | 標的化分子 |
| ES2405944T3 (es) | 2000-11-30 | 2013-06-04 | Medarex, Inc. | Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas |
| US6562576B2 (en) | 2001-01-04 | 2003-05-13 | Myriad Genetics, Inc. | Yeast two-hybrid system and use thereof |
| US20050063948A1 (en) | 2001-03-08 | 2005-03-24 | Dickerson Erin B. | Methods for targeting interleukin-12 to malignant endothelium |
| AU2002344208A1 (en) * | 2001-03-28 | 2002-12-09 | Incyte Genomics, Inc. | Molecules for diagnostics and therapeutics |
| ITTV20010035A1 (it) | 2001-03-30 | 2002-09-30 | Bettio Group Srl | Zanzariera con dispositivo di aggancio e sgancio rapido della barra maniglia |
| WO2002092780A2 (en) | 2001-05-17 | 2002-11-21 | Diversa Corporation | Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof |
| DE60234202D1 (de) | 2001-05-24 | 2009-12-10 | Zymogenetics Inc | Taci-immunoglobulin-fusionsproteine |
| US20030031671A1 (en) | 2001-08-01 | 2003-02-13 | Sydney Welt | Methods of treating colon cancer utilizing tumor-specific antibodies |
| DK1419179T3 (da) | 2001-08-10 | 2010-06-21 | Univ Aberdeen | Antigenbindingsdomæner fra fisk |
| US6797493B2 (en) | 2001-10-01 | 2004-09-28 | Lee-Hwei K. Sun | Fc fusion proteins of human granulocyte colony-stimulating factor with increased biological activities |
| ES2326964T3 (es) | 2001-10-25 | 2009-10-22 | Genentech, Inc. | Composiciones de glicoproteina. |
| AU2003217912A1 (en) | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
| EP2100617A1 (en) | 2002-03-15 | 2009-09-16 | Schering Corporation | Methods of modulating CD200 receptors |
| BR0309145A (pt) | 2002-04-09 | 2005-02-01 | Kyowa Hakko Kogyo Kk | Células das quais o genoma é modificado |
| US7595048B2 (en) | 2002-07-03 | 2009-09-29 | Ono Pharmaceutical Co., Ltd. | Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1 |
| GB2392158B (en) | 2002-08-21 | 2005-02-16 | Proimmune Ltd | Chimeric MHC protein and oligomer thereof |
| JP2006512910A (ja) | 2002-10-23 | 2006-04-20 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | Ａ３４およびａ３３様３ｄｎａ、タンパク質、それらに対する抗体、ならびに同一物を使用した治療方法 |
| US8119117B2 (en) * | 2002-11-12 | 2012-02-21 | Vaxum, Llc | Adenoviral expression vector comprising a CD40L fusion protein adapted to elicit cellular immunity |
| WO2004056875A1 (en) | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
| US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| WO2005003156A1 (en) | 2003-07-04 | 2005-01-13 | Affibody Ab | Polypeptides having binding affinity for her2 |
| AU2003275958A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| US20060134105A1 (en) | 2004-10-21 | 2006-06-22 | Xencor, Inc. | IgG immunoglobulin variants with optimized effector function |
| BRPI0417302A (pt) | 2003-12-05 | 2007-03-06 | Compound Therapeutics Inc | inibidores de receptores de fator de crescimento endotelial vascular do tipo 2 |
| US20050256576A1 (en) | 2004-05-13 | 2005-11-17 | Moskowitz Nathan C | Artificial expansile total lumbar and thoracic discs for posterior placement without supplemental instrumentation and its adaptation for anterior placement of artificial cervical, thoracic and lumbar discs |
| EP2194064A1 (en) | 2004-05-13 | 2010-06-09 | Eli Lilly & Company | FGF-21 fusion proteins |
| SI1781682T1 (sl) | 2004-06-24 | 2013-05-31 | Mayo Foundation For Medical Education And Research | B7-H5, so-stimulatorni polipeptid |
| DK2586456T3 (en) | 2004-10-29 | 2016-03-21 | Ratiopharm Gmbh | Conversion and glycopegylation of fibroblast growth factor (FGF) |
| ES2545533T3 (es) | 2004-11-01 | 2015-09-11 | The Regents Of The University Of California | Composiciones y métodos para modificación de biomoléculas |
| US7700099B2 (en) | 2005-02-14 | 2010-04-20 | Merck & Co., Inc. | Non-immunostimulatory antibody and compositions containing the same |
| WO2006116181A2 (en) * | 2005-04-25 | 2006-11-02 | Trustees Of Dartmouth College | Regulatory t cell mediator proteins and uses thereof |
| US8231872B2 (en) | 2005-04-25 | 2012-07-31 | The Trustees Of Dartmouth College | Regulatory T cell mediator proteins and uses thereof |
| BRPI0611766A2 (pt) | 2005-06-08 | 2011-12-20 | Dana Farber Cancer Inst Inc | métodos e composições para o tratamento de infecções persistentes e cáncer por inibição da rota de morte celular programada |
| WO2007030198A2 (en) | 2005-07-11 | 2007-03-15 | Human Biosystems | Improved methods and solutions for storing donor organs |
| US7531164B2 (en) | 2005-10-21 | 2009-05-12 | Duke University | Preventing bacterial or viral infectivity and composition containing infection preventing additive |
| US7655778B2 (en) | 2006-02-28 | 2010-02-02 | Curonix Co., Ltd. | SISP-1, a novel p53 target gene and use thereof |
| ES2399075T3 (es) | 2006-08-30 | 2013-03-25 | Genentech, Inc. | Anticuerpos multiespecíficos |
| EP1958957A1 (en) | 2007-02-16 | 2008-08-20 | NascaCell Technologies AG | Polypeptide comprising a knottin protein moiety |
| WO2009089004A1 (en) | 2008-01-07 | 2009-07-16 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| EP2321345A1 (en) | 2008-07-28 | 2011-05-18 | Emergent Product Development Seattle, LLC | Multi-specific binding proteins targeting b cell disorders |
| CN102203125A (zh) * | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂及其使用方法 |
| AU2009298122B2 (en) | 2008-10-03 | 2015-01-15 | Emory University | Agonists of toll-like receptor 5 for the treatment of graft-versus-host disease |
| WO2010146059A2 (en) | 2009-06-16 | 2010-12-23 | F. Hoffmann-La Roche Ag | Biomarkers for igf-1r inhibitor therapy |
| IT1395574B1 (it) | 2009-09-14 | 2012-10-16 | Guala Dispensing Spa | Dispositivo di erogazione |
| BR112012024565B1 (pt) | 2010-03-26 | 2022-02-08 | Trustees Of Dartmouth College | Proteína de fusão vista imunossupressora multimérica isolada ou recombinante e composição |
| US20150231215A1 (en) | 2012-06-22 | 2015-08-20 | Randolph J. Noelle | VISTA Antagonist and Methods of Use |
| US10745467B2 (en) | 2010-03-26 | 2020-08-18 | The Trustees Of Dartmouth College | VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders |
| NZ720423A (en) * | 2010-03-26 | 2019-01-25 | Dartmouth College | Vista regulatory t cell mediator protein, vista binding agents and use thereof |
| US20180237525A9 (en) * | 2010-03-26 | 2018-08-23 | Randolph J. Noelle | VISTA Agonist and Methods of Use |
| US20110250215A1 (en) | 2010-04-02 | 2011-10-13 | Athena Discovery, Inc. | Structurally-related relaxin-fusion proteins with extended in vivo half-lives |
| HK1204950A1 (en) | 2012-06-06 | 2015-12-11 | 昂考梅德药品有限公司 | Binding agents that modulate the hippo pathway and uses thereof |
| FI3421486T3 (fi) | 2012-06-22 | 2023-12-15 | Dartmouth College | Uusia vista-ig-rakenteita ja vista-ig:n käyttö autoimmuuni-, allergia- ja tulehdushäiriöiden hoitamiseksi |
| US9890215B2 (en) * | 2012-06-22 | 2018-02-13 | King's College London | Vista modulators for diagnosis and treatment of cancer |
| JP6368308B2 (ja) * | 2012-09-07 | 2018-08-01 | トラスティーズ・オブ・ダートマス・カレッジ | 癌の診断および治療のためのｖｉｓｔａ調節剤 |
| AU2014268298B2 (en) | 2013-05-24 | 2019-01-17 | Medlmmune, Llc | Anti-B7-H5 antibodies and their uses |
| US10273301B2 (en) | 2013-12-24 | 2019-04-30 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments |
| CA2936926C (en) | 2014-01-14 | 2023-08-29 | Mark Spaller | Vista antagonist and methods of use |
| SG11201608303QA (en) * | 2014-04-04 | 2016-11-29 | Del Mar Pharmaceuticals | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer |
| WO2015191881A2 (en) | 2014-06-11 | 2015-12-17 | Green Kathy A | Use of vista agonists and antagonists to suppress or enhance humoral immunity |
| WO2016090347A1 (en) | 2014-12-05 | 2016-06-09 | Immunext, Inc. | Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators |
| US11525000B2 (en) | 2016-04-15 | 2022-12-13 | Immunext, Inc. | Anti-human VISTA antibodies and use thereof |
| WO2017181109A1 (en) | 2016-04-15 | 2017-10-19 | Michael Molloy | Anti-human vista antibodies and use thereof |
| US11649285B2 (en) | 2016-08-03 | 2023-05-16 | Bio-Techne Corporation | Identification of VSIG3/VISTA as a novel immune checkpoint and use thereof for immunotherapy |
-
2011
- 2011-03-25 BR BR112012024565-1A patent/BR112012024565B1/pt active IP Right Grant
- 2011-03-25 CN CN201611048746.5A patent/CN107098958B/zh active Active
- 2011-03-25 AU AU2011230537A patent/AU2011230537C1/en not_active Ceased
- 2011-03-25 JP JP2013502683A patent/JP6034283B2/ja not_active Expired - Fee Related
- 2011-03-25 KR KR1020127027819A patent/KR101882523B1/ko active Active
- 2011-03-25 EP EP11760352.2A patent/EP2552947A4/en not_active Withdrawn
- 2011-03-25 NZ NZ602634A patent/NZ602634A/en not_active IP Right Cessation
- 2011-03-25 NZ NZ737844A patent/NZ737844A/en not_active IP Right Cessation
- 2011-03-25 EP EP16182658.1A patent/EP3153521B1/en active Active
- 2011-03-25 CA CA3079122A patent/CA3079122A1/en active Pending
- 2011-03-25 WO PCT/US2011/030087 patent/WO2011120013A2/en not_active Ceased
- 2011-03-25 MX MX2016011425A patent/MX374075B/es unknown
- 2011-03-25 CA CA2794483A patent/CA2794483C/en active Active
- 2011-03-25 US US13/637,381 patent/US9631018B2/en active Active
- 2011-03-25 MX MX2012011089A patent/MX342017B/es active IP Right Grant
- 2011-03-25 CN CN201180025788.6A patent/CN103119054B/zh active Active
-
2012
- 2012-09-24 IL IL222118A patent/IL222118B/en active IP Right Grant
-
2016
- 2016-04-07 AU AU2016202172A patent/AU2016202172B2/en not_active Ceased
- 2016-07-28 JP JP2016147969A patent/JP6175170B2/ja active Active
-
2017
- 2017-03-23 US US15/467,118 patent/US10781254B2/en active Active
- 2017-07-06 JP JP2017132677A patent/JP6712716B2/ja active Active
-
2018
- 2018-04-03 AU AU2018202330A patent/AU2018202330B2/en not_active Ceased
- 2018-06-20 IL IL260184A patent/IL260184B/en active IP Right Grant
-
2020
- 2020-04-17 JP JP2020073996A patent/JP2020128381A/ja active Pending
- 2020-04-29 AU AU2020202838A patent/AU2020202838A1/en not_active Abandoned
- 2020-09-17 US US17/023,927 patent/US20210139578A1/en not_active Abandoned
-
2023
- 2023-05-12 AU AU2023202967A patent/AU2023202967A1/en not_active Abandoned
- 2023-09-28 US US18/476,403 patent/US20240228609A9/en active Pending